Popular on eTradeWire
- Stephanie Peppers Launches Rethread Chronicles - 182
- Cozy Up with Adirondack Fragrance Farm's New Soy Wax Melts - 120
- History Matters: Book Recommendations for September 2024 - 119
- Allegiant Management Group Launches New Website Following Recent Rebranding - 104
- Mounts Botanical Garden to Present RIBBIT THE EXHIBIT II with 18 Larger-Than-Life Frog Sculptures
- Atlas Elite Entertainment Releases New Single "Forever"
- Wagoner Roofing Launches New Website
- Colony Ridge Welcomes A Second DG Market!
- Title Alliance Announces Strategic Consolidation of their Arizona Joint Ventures to Enhance Business
- Beyond Wellness Chiropractic Voted Best Chiropractor in Charleston for 2024
Similar on eTradeWire
- Hypothesis by Richard H. Davis: Carrier Pigeons and Milk Immunity
- IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
- Terumo Blood and Cell Technologies and Nova Biomedical collaborate on automated cell culture sensing
- AI Team from "PersonalAIze" Expert Assessment; Groundbreaking AI Platform Starting with Early Cancer Detection: Renovaro; Stock Symbol: RENB
- Bioasis Announces Resignation of Board of Directors
- Elevation Strategic Development, LLC Expands with New Subsidiary and Enhanced Service Offerings
- NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
- Creative Biolabs presents codes ruling antibody discovery
- Planned Spin-Out to Focus on Gene Therapy for Type 1 and 2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex: Stock Symbol: GNPX
- Logical Biological appoints Stephane Argivier as new CEO
Quantoom Biosciences & Tiamat Sciences Announce Strategic Partnership to Revolutionize mRNA Product
eTradeWire News/10771118
DURHAM, N.C. - eTradeWire -- Quantoom Biosciences and Tiamat Sciences Announce Strategic Partnership to Revolutionize mRNA Production
Quantoom Biosciences S.A. ("Quantoom"), part of Univercells S.A., focused on mRNA production technologies for vaccines and therapeutics, and Tiamat Sciences, a plant-based platform and product life sciences company, are thrilled to announce a groundbreaking partnership aimed at bringing mRNA technology to a broader audience.
Under this partnership, Tiamat Sciences will work on feasibility evaluation, development and supply of a series of key enzymes in support of the innovative platform production processes developed at Quantoom Biosciences. This collaboration is set to revolutionize the way mRNA is produced, making it more efficient, cost-effective, and environmentally sustainable.
A New Era in mRNA Production
Quantoom Biosciences and Tiamat Sciences are at the forefront of innovation in mRNA technology. By leveraging Tiamat's plant-based expression systems, the partnership aims to significantly enhance innovation within mRNA production processes, which is crucial for the development of vaccines and therapeutics.
More on eTradeWire News
Statements from Leadership
Quantoom Biosciences CEO, Jose Castillo, stated, "We are thrilled to engage in this collaboration with Tiamat Sciences. By combining our expertise in mRNA manufacturing with Tiamat Sciences' innovative approach to enzyme development, we believe we can significantly enhance our ability to deliver groundbreaking solutions in the mRNA field. This strategic partnership represents a tremendous opportunity to improve access to healthcare and further increase the affordability of new treatments ."
Tiamat Sciences CEO, France-Emmanuelle Adil, added, "We are proud to join forces with Quantoom Biosciences. This partnership not only underscores the scientific milestones we have achieved but also highlights the immense potential of plant-based expression systems in transforming the future of pharmaceutical production."
Revolutionizing Pharmaceutical Production
The collaboration between Quantoom and Tiamat is poised to set new standards in the pharmaceutical industry. By utilizing plant-based expression systems for essential reagents, the partnership demonstrates a commitment to sustainability and innovation, ensuring that the future of protein production is both environmentally friendly and highly efficient.
More on eTradeWire News
About Quantoom Biosciences
Quantoom Biosciences is reinventing mRNA production by developing an RNA platform that includes RNA manufacturing and formulation. Their RNA manufacturing technology, Ntensify™, encompasses process, equipments, mixes of reagents, and disposables designed for seamless integration across various scales, making it an ideal choice from research to to large-scale manufacturing. Ncapsulate™ is a fully integrated and automated system tailored for GMP mRNA formulation and designed to meet the rigorous standards of both clinical and commercial manufacturing. Quantoom Biosciences's facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences group with the mission of making biologics accessible to all.
https://quantoom.com/
About Tiamat Sciences
Tiamat Sciences is a pioneering life sciences company that uses plant-based platforms to produce reagents. Their innovative approach is transforming the way proteins are produced, emphasizing efficiency, cost-effectiveness, and environmental sustainability. Tiamat Sciences has recently made notable advancements by expressing T7 polymerase, a crucial enzyme for mRNA vaccine synthesis.
https://www.tiamat-sciences.com/
Quantoom Biosciences S.A. ("Quantoom"), part of Univercells S.A., focused on mRNA production technologies for vaccines and therapeutics, and Tiamat Sciences, a plant-based platform and product life sciences company, are thrilled to announce a groundbreaking partnership aimed at bringing mRNA technology to a broader audience.
Under this partnership, Tiamat Sciences will work on feasibility evaluation, development and supply of a series of key enzymes in support of the innovative platform production processes developed at Quantoom Biosciences. This collaboration is set to revolutionize the way mRNA is produced, making it more efficient, cost-effective, and environmentally sustainable.
A New Era in mRNA Production
Quantoom Biosciences and Tiamat Sciences are at the forefront of innovation in mRNA technology. By leveraging Tiamat's plant-based expression systems, the partnership aims to significantly enhance innovation within mRNA production processes, which is crucial for the development of vaccines and therapeutics.
More on eTradeWire News
- Blueprint Expands Digital Event Advertising Services to Enhance Sponsorship Sales
- TopFan Enhances Podcasting Experience with the Ultimate Fan Club Platform
- Alana Winns Steps Down as Editor-in-Chief and Chief Content Officer of Career Communications Group
- TopFan Revolutionizes Fan Engagement with the Ultimate Fan Club Platform for Musicians
- The Giving Edge: Is Leveraging Outrageous Kindness the Missing Link for Corporate ROI?
Statements from Leadership
Quantoom Biosciences CEO, Jose Castillo, stated, "We are thrilled to engage in this collaboration with Tiamat Sciences. By combining our expertise in mRNA manufacturing with Tiamat Sciences' innovative approach to enzyme development, we believe we can significantly enhance our ability to deliver groundbreaking solutions in the mRNA field. This strategic partnership represents a tremendous opportunity to improve access to healthcare and further increase the affordability of new treatments ."
Tiamat Sciences CEO, France-Emmanuelle Adil, added, "We are proud to join forces with Quantoom Biosciences. This partnership not only underscores the scientific milestones we have achieved but also highlights the immense potential of plant-based expression systems in transforming the future of pharmaceutical production."
Revolutionizing Pharmaceutical Production
The collaboration between Quantoom and Tiamat is poised to set new standards in the pharmaceutical industry. By utilizing plant-based expression systems for essential reagents, the partnership demonstrates a commitment to sustainability and innovation, ensuring that the future of protein production is both environmentally friendly and highly efficient.
More on eTradeWire News
- TopFan Empowers Music Artists with an All-in-One Fan Club Platform
- TopFan Empowers Influencers with the Ultimate Fan Club Platform
- TradeTek 1.4 Construction Estimating Software
- Holman UMC Offerings for Registered and Aspiring Voters
- Russ Napolitano Combines Creativity, Humor, and Philanthropy in "Book of Those Words"
About Quantoom Biosciences
Quantoom Biosciences is reinventing mRNA production by developing an RNA platform that includes RNA manufacturing and formulation. Their RNA manufacturing technology, Ntensify™, encompasses process, equipments, mixes of reagents, and disposables designed for seamless integration across various scales, making it an ideal choice from research to to large-scale manufacturing. Ncapsulate™ is a fully integrated and automated system tailored for GMP mRNA formulation and designed to meet the rigorous standards of both clinical and commercial manufacturing. Quantoom Biosciences's facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences group with the mission of making biologics accessible to all.
https://quantoom.com/
About Tiamat Sciences
Tiamat Sciences is a pioneering life sciences company that uses plant-based platforms to produce reagents. Their innovative approach is transforming the way proteins are produced, emphasizing efficiency, cost-effectiveness, and environmental sustainability. Tiamat Sciences has recently made notable advancements by expressing T7 polymerase, a crucial enzyme for mRNA vaccine synthesis.
https://www.tiamat-sciences.com/
Source: Tiamat Sciences Corporation
Filed Under: Biotech
0 Comments
Latest on eTradeWire News
- DTC Computer Supplies Announces Name Change to DES Technologies
- Robert Maloy Announces Candidacy for City Council in Windcrest
- Arkansas Hose Pro Celebrates Successful First Year with Fleet Expansion
- Holabird's timed, online-only Cauldron of Curiosities auction, October 19-20, features numismatics, Western Americana, more
- One Of The Largest Native American Burial Sites In The United States Moves A Step Closer To National Recognition
- Support CCAE Foundation's Continued Leadership of California Center for the Arts
- 2024 ASA Litigation in Valuation Conference to Focus on Winning Strategies for High-Stakes Cases
- Online Traffic For Insurance Agents Grows Significantly As AEP Approaches
- SBAC Onboards New Board and Loan Committee Members
- The National Lottery Heritage Fund award £3.5 million to support Linkage Weelsby Hall development
- Join ASA's Winter Fair Value Conference for Insights into Evolving Standards and Best Practices
- Transcend Engineering Announces Small Business Innovation Research Phase 2 Award from NOAA
- JMAC Shares Common Mistakes When Practicing Iaido
- Xmas Delights Shares the Benefits of Hiring Professional Light Installers
- Cummings Graduate Institute for Behavioral Health Studies Announces New Book: Integrated Behavioral Health: Applying the Biodyne Mindset in Healthcare
- Dam Group Shares the Best Places to Be this Fall in Ann Arbor!
- Lead at Any Level® Expands DBE/ACDBE Certifications to Fifteen States
- SureFlow to Showcase AI and Eco-Technology Energy Management Solutions at GITEX 2024
- Dive into the Spooky Season with Limited Edition Porpoise of Halloween NFTs by Scott Atomic
- CE-Credited Training Course on Advanced Implant Techniques to Be Held at ICOI Central Office